TOday’s Movers: Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Reiterated at Cantor Fitzgerald; $36.0000 Target Price Indicates 71.43 % Potential

May 17, 2018 - By Kurt Siggers

Abeona Therapeutics Inc. (NASDAQ:ABEO) Logo

Abeona Therapeutics (NASDAQ:ABEO) Rating Reaffirmed

Cantor Fitzgerald now has a $36.0000 PT on shares of Abeona Therapeutics (NASDAQ:ABEO). The PT suggests a potential upside of 71.43 % from the last price of Abeona Therapeutics (NASDAQ:ABEO). This rating was disclosed to clients in an analyst report on 15 May.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Among 4 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics has $36.0 highest and $26.0 lowest target. $30’s average target is 42.86% above currents $21 stock price. Abeona Therapeutics had 14 analyst reports since November 21, 2017 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $28.0 target in Tuesday, November 21 report. The firm earned “Buy” rating on Monday, May 14 by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Monday, April 2. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Thursday, April 12 by H.C. Wainwright. The company was maintained on Monday, January 29 by Cantor Fitzgerald. H.C. Wainwright maintained it with “Buy” rating and $3000 target in Friday, April 20 report. The rating was maintained by Cantor Fitzgerald on Wednesday, February 7 with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, February 8 report. The firm has “Buy” rating by H.C. Wainwright given on Thursday, May 3. Cantor Fitzgerald maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) rating on Tuesday, March 20. Cantor Fitzgerald has “Buy” rating and $36.0 target.

The stock increased 2.44% or $0.5 during the last trading session, reaching $21. About 780,550 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 188.66% since May 17, 2017 and is uptrending. It has outperformed by 177.11% the S&P500.

Analysts await Abeona Therapeutics Inc. (NASDAQ:ABEO) to report earnings on August, 21. They expect $-0.20 earnings per share, up 4.76 % or $0.01 from last year’s $-0.21 per share. After $-0.18 actual earnings per share reported by Abeona Therapeutics Inc. for the previous quarter, Wall Street now forecasts 11.11 % negative EPS growth.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $993.41 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

More notable recent Abeona Therapeutics Inc. (NASDAQ:ABEO) news were published by: Streetinsider.com which released: “Viking Global’s 13F Shows New Stakes in Alibaba (BABA), BioMarin (BMRN) and Western Digital (WDC), Increase in …” on May 15, 2018, also Seekingalpha.com with their article: “Your Daily Pharma Scoop: Abeona’s ABO-202, Revance Update, Ionis/Biogen’s New Collaboration” published on April 23, 2018, Seekingalpha.com published: “Krystal Biotech: Important Catalyst And Value Inflection Point Approaching” on May 08, 2018. More interesting news about Abeona Therapeutics Inc. (NASDAQ:ABEO) were released by: Globenewswire.com and their article: “Abeona Therapeutics Announces Upcoming Presentations” published on May 08, 2018 as well as Streetinsider.com‘s news article titled: “Abeona Therapeutics (ABEO) Tops Q1 EPS by 1c” with publication date: May 11, 2018.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.